Shares of Dynatrace, Inc. (NYSE:DT – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the twenty-three ratings firms that are covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and seventeen have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $59.70.
DT has been the subject of a number of analyst reports. BMO Capital Markets upped their price objective on Dynatrace from $49.00 to $53.00 and gave the stock an “outperform” rating in a research note on Thursday, August 8th. Scotiabank upped their price objective on Dynatrace from $52.00 to $55.00 and gave the stock a “sector outperform” rating in a research note on Thursday, August 8th. Needham & Company LLC restated a “hold” rating on shares of Dynatrace in a research note on Tuesday, August 6th. Wedbush restated a “neutral” rating and set a $55.00 price objective on shares of Dynatrace in a research note on Thursday, August 8th. Finally, Guggenheim reduced their target price on Dynatrace from $60.00 to $55.00 and set a “buy” rating on the stock in a research report on Tuesday, July 16th.
Get Our Latest Stock Analysis on DT
Insider Activity
Hedge Funds Weigh In On Dynatrace
Hedge funds have recently bought and sold shares of the business. Geneos Wealth Management Inc. boosted its position in Dynatrace by 76.7% during the first quarter. Geneos Wealth Management Inc. now owns 530 shares of the company’s stock worth $25,000 after purchasing an additional 230 shares in the last quarter. Versant Capital Management Inc lifted its position in shares of Dynatrace by 3,813.3% in the second quarter. Versant Capital Management Inc now owns 587 shares of the company’s stock valued at $26,000 after acquiring an additional 572 shares in the last quarter. Cullen Frost Bankers Inc. purchased a new position in shares of Dynatrace in the second quarter valued at approximately $26,000. DSM Capital Partners LLC purchased a new position in shares of Dynatrace in the fourth quarter valued at approximately $28,000. Finally, Rise Advisors LLC purchased a new position in shares of Dynatrace in the first quarter valued at approximately $30,000. Hedge funds and other institutional investors own 94.28% of the company’s stock.
Dynatrace Trading Up 0.9 %
Shares of DT stock opened at $52.49 on Wednesday. Dynatrace has a twelve month low of $39.42 and a twelve month high of $61.41. The stock has a market capitalization of $15.65 billion, a price-to-earnings ratio of 100.94, a P/E/G ratio of 7.63 and a beta of 1.05. The stock has a fifty day simple moving average of $47.97 and a two-hundred day simple moving average of $46.61.
Dynatrace (NYSE:DT – Get Free Report) last issued its earnings results on Wednesday, August 7th. The company reported $0.33 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.04. The business had revenue of $399.20 million during the quarter, compared to analysts’ expectations of $392.22 million. Dynatrace had a return on equity of 9.77% and a net margin of 10.36%. The business’s revenue for the quarter was up 19.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.16 EPS. Research analysts predict that Dynatrace will post 0.71 EPS for the current fiscal year.
About Dynatrace
Dynatrace, Inc provides a security platform for multicloud environments. It operates Dynatrace, a security platform, which provides application and microservices monitoring, runtime application security, infrastructure monitoring, log management and analytics, digital experience monitoring, digital business analytics, and cloud automation.
Featured Stories
- Five stocks we like better than Dynatrace
- Best Stocks Under $10.00
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- What is a support level?
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Investing In Automotive Stocks
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Dynatrace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynatrace and related companies with MarketBeat.com's FREE daily email newsletter.